Drug intelligence / Profile preview

ondansetron + sertraline

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Ondansetron + sertraline is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Ondansetron is a selective serotonin 5-HT3 receptor antagonist primarily used to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Sertraline is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression, anxiety disorders, and related conditions. When used together, these agents can increase serotonergic activity in the central nervous system. This combination raises the risk of serotonin syndrome—a potentially serious condition characterized by symptoms such as agitation, confusion, rapid heart rate, dilated pupils, muscle rigidity or tremor—due to additive effects on serotonin levels[2][4][5]. The use of this combination should be carefully monitored by healthcare professionals.

02

Targets

SERT (Sodium-dependent serotonin transporter)HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on ondansetron + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ondansetron + sertraline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call